Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 17 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

5 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

5 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

9(56.3%)

Phase 3

5(31.3%)

Phase 1

2(12.5%)

16Total

Phase 2(9)

Phase 3(5)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT07529613Phase 1Completed

Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma

Role: lead

NCT05394740Phase 1Completed

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Role: lead

NCT05696548Phase 2Active Not Recruiting

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Role: lead

NCT04745988Phase 2Active Not Recruiting

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Role: lead

NCT05034887Phase 2Active Not Recruiting

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Role: lead

NCT05694819Phase 2Completed

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Role: lead

NCT04457297Phase 3Completed

Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

Role: lead

NCT07018570Phase 2Recruiting

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

Role: lead

NCT07100704Phase 2Recruiting

Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab

Role: lead

NCT04879368Phase 3Active Not Recruiting

RegoNivo vs Standard of Care Chemotherapy in AGOC

Role: collaborator

NCT03609359Phase 2Completed

Lenvatinib and Pembrolizumab Simultaneous Combination Study

Role: lead

NCT05646511Phase 3Recruiting

TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer